Hunt Nimrata

Hunt Nimrata, Executive Vice President at IDEXX Laboratories (IDXX), has been a consistent seller of company stock over the past year, with Form 4 filings showing zero open-market purchases against approximately $14.8 million in total sales. The most recent activity, clustered in late February and early March 2026, saw two open-market sales totaling roughly $2.9 million—$1.12 million on March 3 and $1.78 million on February 26. That selling follows a heavier November 2025 session on November 7, when four separate S-code transactions liquidated about $6.6 million in IDXX shares, the largest single-day disposition in the reviewed period. The pattern is punctuated by routine, non-discretionary filings that do not reflect directional conviction. On February 14, 2026, Nimrata exercised five option tranches (M-code, all valued at $0) and had $726,270 in shares withheld to cover taxes (F-code), while four grant awards (A-code) were recorded on February 12. These mechanical transactions—compensation, exercises, and tax withholding—are standard for executives and do not alter the fundamental sell-side bias. The August 2025 activity reinforces that trend: three open-market sales between August 6 and August 11 totaled roughly $5.3 million, alongside three small option exercises valued near $100,000 each. Across all 46 filings, every discretionary trade has been a sale of IDXX common stock, with no P-code purchases or acquisitions of new shares. The dollar-weighted flow is overwhelmingly one-directional, concentrated in three distinct selling windows—August 2025, November 2025, and February-March 2026—with the November cluster alone accounting for nearly half of the total sell value. While the option exercises and grants add share volume, they are compensatory in nature; the open-market sales represent the only active portfolio decisions, and they have been uniformly bearish in direction.